The Group’s corporate headquarters sits within the Tissue Regenix UK base, situated in Leeds at a specially modified 18,000 sq ft facility.

Responsible for all porcine tissue device manufacturing, this facility currently produces SurgiPure^® XD for export to the US, and also OrthoPure^™ XT in preparation for the European launch following the CE mark approval. With strong connections to the University of Leeds, this facility also acts as the research and development hub for potential future portfolio developments.

The facility received a Human Tissue Authority license in 2018 allowing it to function as the Europeon base for import and distribution of CellRight’s osteobiologics portfolio.